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Introduction
In the United States approximately 60-80% of patients diagnosed with breast cancer will receive adjuvant chemotherapy. Of these patients more than 30% will experience shortterm and long-term cognitive impairment (e.g., problems with memory and concentration) for at least 1-2 years after completion of chemotherapy. Despite the effects cognitive impairment can have on a patient's quality of life very few studies have been conducted to learn more about this side effect.
This study aims to evaluate the pathophysiology of cognitive dysfunction in patients receiving adjuvant chemotherapy with Adriamycin and cyclophosphamide for breast cancer using [150] water PET scans and neuropsychological tests.
A total of 24 eligible patients with early stage breast cancer, who are candidates for adjuvant chemotherapy, will be enrolled in this study. Each patient will undergo [150] water PET scans at baseline and after completing 4 cycles of adjuvant chemotherapy to measure the differences in regional blood flow of the brain during working memory. Neuropsychological tests will be done to determine attention, speeded processing, memory, and executive functions outside of the [150] water PET scans.
Investigators will analyze several categories of data once the accrual goal (24 patients) is met: * Participant Characteristics (demographics)
• Neuropsychological Measures (differences in attention/processing, memory, and frontal lobe processing) * PET Behavioral Performance (total number of responses and correct responses will be recorded * t-Statistic Volumes (examine patterns of neural activation) * Group and Time Comparisons (to test if there are significant differences between the two times for peaks obtained by the t-Statistic volumes) * Exploratory Analysis (explore relationship between changes in blood flow during working memory and cognitive defects)
The data for this study is entered into an electronic database that is password protected. The data manager is responsible for maintenance of this database as new information is provided per the Principal Investigator or study coordinator. All data is kept in a secure location at West Virginia University in the Clinical Trials Research Unit. Additionally, some PET scan data and neuropsychological data will be kept in a secure location in the Center for Advanced Imaging (in Dr. Marc Haut's office) at West Virginia University.
In April 2004 this study was amended due to published data regarding the safety of Epoetin alfa (EPO). This data showed that patients with normal hemoglobin levels who receive treatment with EPO have increased morbidity and mortality. Due to this information the Investigators were prompted to change the protocol to look at pre-post chemotherapy changes in the brain with PET scan, but without treating patients with EPO. Therefore the protocol aims to understand the pathophysiology of cognitive dysfunction without studying the role of EPO. All three patients were notified of this change to the protocol.
Body Task 1. Study the baseline cognitive function 9 Three patients with early stage breast cancer receiving adjuvant chemotherapy have been enrolled in this study prior to the amendment. * Baseline cognitive function assessments with neuropsychological measures have been completed by each patient. e The baseline study of regional blood flow of the brain using [150] water PET scans during working memory has been completed by each patient. 
